Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) gets downgraded to Hold by Needham & Company LLC with a price target of $22.20

ME Staff
-
0

Analyst Ratings For Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)

Today, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) stock was downgraded by Needham & Company LLC from Buy to Hold with a price target of $22.20.

There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is Hold with a consensus target price of $22.55 per share, a potential 6.47% upside.

Some recent analyst ratings include

  • 3/13/2019-Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) gets downgraded to Hold by Needham & Company LLC with a price target of $22.20
  • 3/13/2019-Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) gets downgraded to Neutral by Piper Jaffray Companies with a price target of $23.00
  • 11/14/2018-Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) had its Buy rating reiterated by Jefferies Financial Group with a $26.00 price target
  • 11/9/2018-Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) had its Buy rating reiterated by Wells Fargo & Co
  • 3/13/2018-Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) had its Market Perform ➝ Market Perform rating reiterated by BMO Capital Markets with a $19.00 price target
  • 11/9/2017-Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) gets downgraded to Market Perform by Raymond James with a price target of $18.00
  • On 3/4/2019 William J Peters, CFO, sold 1,500 with an average share price of $25.36 per share and the total transaction amounting to $38,040.00.
  • On 3/1/2019 Jason B Shandell, Insider, sold 7,500 with an average share price of $24.99 per share and the total transaction amounting to $187,425.00.
  • On 3/1/2019 Rong Zhou, EVP, sold 3,200 with an average share price of $25.00 per share and the total transaction amounting to $80,000.00.
  • On 2/15/2019 William J Peters, CFO, sold 10,016 with an average share price of $24.37 per share and the total transaction amounting to $244,089.92.
  • On 2/14/2019 Jason B Shandell, Insider, sold 7,519 with an average share price of $23.99 per share and the total transaction amounting to $180,380.81.
  • On 2/14/2019 Yakob Liawatidewi, SVP, sold 8,868 with an average share price of $23.86 per share and the total transaction amounting to $211,590.48.
  • On 2/12/2019 Yakob Liawatidewi, SVP, sold 4,000 with an average share price of $23.70 per share and the total transaction amounting to $94,800.00.

About Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Recent Trading Activity for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
Shares of Amphastar Pharmaceuticals Inc closed the previous trading session at 21,14 −3,02 12,52 % with 22.54 shares trading hands.